INCR
InterCure Ltd.
There isn't enough reported data to score INCR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
INCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
INCR's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INCR PE Valuation
INCR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
INCR Forward outlook
There aren't enough analyst estimates for INCR to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
INCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.32 | -$0.18 |
| Q4 2023 | -$2.14 | -238% |
| Q4 2022 | $1.55 | +812% |
| Q4 2021 | $0.17 | +$2.61 |
| Q4 2020 | -$2.44 | -$2.25 |
| Q3 2020 | -$3.93 | -1059% |
| Q2 2020 | -$5.04 | -567% |
| Q1 2020 | -$5.75 | -459% |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 195% for INCR versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
INCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $75M | -33% |
| Q4 2023 | $111.7M | -8.5% |
| Q4 2022 | $122.1M | +77% |
| Q4 2021 | $69M | +711% |
| Q4 2020 | $8.5M | +1382% |
| Q3 2020 | $7.1M | +766% |
| Q2 2020 | $3.5M | +303% |
| Q1 2020 | $1.3M | +147% |
INCR has the stronger quarterly revenue trend. Revenue is up 782% for INCR versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -28% | -56 points |
| Q4 2023 | -12% | -22 points |
| Q4 2022 | 13% | +21 points |
| Q4 2021 | 13% | +1125 points |
| Q4 2020 | 28% | +765 points |
| Q3 2020 | 11% | +566 points |
| Q2 2020 | -7.6% | +363 points |
| Q1 2020 | -1113% | -3300 points |
INCR's operating margin was −28% last quarter, down 56 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
INCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$22.4M | -$4.7M |
| Q4 2023 | -$17.7M | -278% |
| Q4 2022 | $9.9M | +187% |
| Q4 2021 | $3.5M | +136% |
| Q4 2020 | $1.5M | -84% |
| Q3 2020 | $525.2K | +$5.5M |
| Q2 2020 | -$2.9M | +$1.4M |
| Q1 2020 | -$3.1M | -$2.3M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with INCR at down 3,189%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
INCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +59.3K shares |
| 1 year | +81% | +4.1M shares |
| 3 years | +138% | +5.3M shares |
| 5 years | +256% | +6.6M shares |
| Available history | +344% | +7.1M shares |
INCR has 9M diluted shares, up 81% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over INCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.1x | Net Cash |
| Q4 2021 | -3.2x | Net Cash |
| Q4 2020 | -3.7x | Net Cash |
| Q3 2019 | -0.4x | Net Cash |
| Q2 2019 | -2.1x | Net Cash |
| Q1 2019 | 0.3x | Very low |
| Q4 2016 | -0.4x | Net Cash |
INCR has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
INCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 13.5 | Oversold |
INCR's weekly RSI is 42 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INCR PE vs Healthcare Sector
| Metric | INCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INCR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 12% below |
| 20 week MA | $4.83 | 18% below |
| 50 week MA | $4.77 | 17% below |
| 100 week MA | $6.21 | 36% below |
| 200 week MA | $8.06 | 51% below |
INCR is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over INCR on trend strength, trading above more of its moving averages.
INCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.45 | $6.00 | +10% |
| 2021 | $6.00 | $36.0 | +500% |
| 2022 | $36.0 | $19.2 | -47% |
| 2023 | $19.2 | $6.45 | -66% |
| 2024 | $6.45 | $8.15 | +26% |
| 2025 | $8.15 | $5.65 | -31% |
| 2026 YTD | $5.65 | $3.98 | -30% |
INCR's yearly returns have swung widely, from +500% in 2021 to −66% in 2023. It's down 30% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INCR on returns for 2026, with the stronger performance.